Switching between cyclosporin formulations. What are the risks?

Drug Safety

Volumn 16, Issue 6, 1997, Pages 366-373

  Olyaei, Ali J ^a   DeMattos, Angelo M ^a   Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ALLOGRAFT; AREA UNDER THE CURVE; CANCER; CHOLESTASIS; CHRONIC KIDNEY DISEASE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MONITORING; DRUG TOXICITY; GRAFT FAILURE; GRAFT SURVIVAL; HEADACHE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INFECTION; KIDNEY TRANSPLANTATION; MICROEMULSION; NAUSEA; PARESTHESIA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SEIZURE; SURGICAL TECHNIQUE; SURVIVAL; TREMOR;

EID: 0030803356     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199716060-00003     Document Type: Review

References (44)

1. Thiel G, Bock A, Spondlin M, et al. Long-term benefits and risks of cyclosporine A (Sandimmune®): an analysis at 10 years. Transplant Proc 1994; 26: 2493-8
2. Kahan BD. Cyclosporine. N Engl J Med 1989; 321: 1725-38
3. Beveridge T. Clinical development of cyclosporine. Transplant Proc 1992; 24: 64-6
4. Rossi SJ, Schroeder TJ, Hariharan S, et al. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf 1993; 9: 104-31
5. de Mattos AM, Olyaci AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996; 28: 631-67
6. Yee GC, Salomon DR. Applied pharmacokinetics - principles of therapeutic drug monitoring. In: Evans WE, Schentag JJ, Jusko WJ, editors: Cyclosporine. Vancouver: Applied Therapeutics Inc., 1992: 1-40
7. Tredger JM. Using cyclosporine neoral immediately after liver transplantation. Ther Drug Monit 1995; 17: 638-41
8. Johnston A, Reynold L, Wright DL, et al. Pharmacokinetics of cyclosporin in heart transplant patients after administration of Sandimmune® and a new oral formulation Neoral® (abstract). Ther Drug Monit 1995; 17: 415
9. Klauser R, Irschik H, Kletzmayr J, et al. Neoral: a new microemulsion formula of cyclosporine A. Interpatient pharmacokinetic variability in renal transplant recipients. Transplant Proc 1995; 27: 3427-9
10. Noble S, Markham A. Cyclosporin: a review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®). Drugs 1995; 50: 924-41
11. Awni WM. Pharmacodynamic monitoring of cyclosporin. Clin Pharmacokinet 1992; 23: 428-48
12. Graham RM. Cyclosporine: mechanisms of action and toxicity. Cleve Clin J Med 1994; 61: 308-13
13. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472-95
14. Tsunoda SM, Aweeka FT. The use of therapeutic drug monitoring to optimise immunosuppressive therapy. Clin Pharmacokinet 1996; 30: 107-40
15. Levy GA, Grant D. Neoral® in liver transplantation. Transplant Proc 1996; 28: 1019-21
16. Whitington PF, Emond JC, Whitington SH, et al. Small-bowel length and the dose of cyclosporine in children after liver transplantation. N Engl J Med 1990; 322: 733-8
17. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985; 40: 457-76
18. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631-44
19. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-18
20. Kahan BD, Kramer WG, Wideman CA. Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. Transplant Proc 1986; 18: 115-9
21. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine. Transplantation 1996; 62: 599-606
22. Nankivell BJ, Hibbins M, Chapman JR. Diagnostic, utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 1994; 58: 989-96
23. Amante AJ, Kahan BD. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate post-transplant period. Clin Chem 1996; 42: 1294-6
24. Kovarik JM, Meuller EA, Johnston A, et al. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy 1993; 13: 613-7
25. Freeman D, Grant D, Levy G, et al. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit 1995; 17: 213-6
26. Kovarik JM, Meuller EA, van Bree JB, et al. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994; 16: 232-7
27. Barone G, Chang CT, Choc MGJ, et al. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. Transplantation 1996; 61: 875-80
28. Kovarik JM, Meuller EA, van Bree JB, et al. Reduced inter-and intra-individual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444-6
29. Kovarik JM, Mueller EA, van Bree JB, et al. Cyclosporin pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658-63
30. Mueller EA, Kovarik JM, van Bree JB, et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients: a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57: 1178-82
31. Bennett WM, DeMattos A, Norman DJ. Which cyclosporin formulation [letter]? Lancet 1996; 348: 205
32. Filler G, Ehrich J. Which cyclosporin formulation? [letter] Lancet 1996; 348: 1177
33. Gennery A, O'Sullivan J, O'Brien C, et al. Which cyclosporin formulation? [letter] Lancet 1996; 348: 1177
34. Neumayer HH, Farber L, Budde K, et al. Long-term results of conversion from existing to microemulsion formulation of cyclosporine. Transplant Proc 1996; 28: 2207-13
35. Feutren G, Wong R, Jin J, et al. Safety and tolerability of Neoral in transplant recipients. Transplant Proc 1996; 28: 2177-82
36. Neumayer HH, Budde K, Farber L, et al. Conversion to microemulsion formulation cyclosporine in stable renal transplant patients: results after one year. Clin Nephrol 1996; 45: 326-31
37. Bennett WM, deMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-100
38. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182-93
39. Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis 1994; 23: 471-5
40. English J, Evan A, Houghton DC, et al. Cyclosporine-induced acute renal dysfunction in the rat: evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135-41
41. Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43: 706-11
42. Curtis JJ, Luke RG, Dubovsky E, et al. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; II: 477-9
43. Burdmann EA, Andoh TF, Nast CC, et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491-9
44. Bunke M, Sloan R, Brier M, et al. An improved glomerular filtration rate in cardiac transplant recipients with once-a-day cyclosporine dosing. Transplantation 1995; 59: 537-40